Predictors of distant metastatic recurrence in head and neck cutaneous squamous cell carcinoma with lymph node metastases treated with curative intent: A multicenter study.
cutaneous squamous cell carcinoma
distant metastases
head and neck cancer
lymph node metastasis
prognosis
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
revised:
06
07
2024
received:
17
05
2024
accepted:
28
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
aheadofprint
Résumé
We aimed to identify predictors of distant metastatic recurrence (DMR) in patients with head and neck cutaneous squamous cell carcinoma (HNcSCC) with nodal metastases treated with curative intent. Predictors of DMR were identified using Cox regression in a multicenter study of 1151 patients. The 5-year risk of DMR was 9.6%. On multivariate analysis, immunosuppression (HR 2.93; 95% CI: 1.70-5.05; p < 0.001), nodal size >6 cm [versus ≤3 cm (HR 2.77; 95% CI: 1.09-7.03; p = 0.032)], ≥5 nodal metastases [versus 1-2 (HR 2.79; 95% CI: 1.63-4.78; p < 0.001)], and bilateral disease (HR 3.11; 95% CI: 1.40-6.90; p = 0.005) predicted DMR. A DMR risk score was developed that stratified risk from 6.6% (no risk factors) to 100% (≥3 risk factors) (p < 0.001). The risk of DMR in nodal metastatic HNcSCC increases with immunosuppression, nodal size >6 cm, ≥5 nodal metastases, and bilateral disease. A simple DMR risk score estimated prior to treatment may be clinically useful.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to identify predictors of distant metastatic recurrence (DMR) in patients with head and neck cutaneous squamous cell carcinoma (HNcSCC) with nodal metastases treated with curative intent.
METHODS
METHODS
Predictors of DMR were identified using Cox regression in a multicenter study of 1151 patients.
RESULTS
RESULTS
The 5-year risk of DMR was 9.6%. On multivariate analysis, immunosuppression (HR 2.93; 95% CI: 1.70-5.05; p < 0.001), nodal size >6 cm [versus ≤3 cm (HR 2.77; 95% CI: 1.09-7.03; p = 0.032)], ≥5 nodal metastases [versus 1-2 (HR 2.79; 95% CI: 1.63-4.78; p < 0.001)], and bilateral disease (HR 3.11; 95% CI: 1.40-6.90; p = 0.005) predicted DMR. A DMR risk score was developed that stratified risk from 6.6% (no risk factors) to 100% (≥3 risk factors) (p < 0.001).
CONCLUSIONS
CONCLUSIONS
The risk of DMR in nodal metastatic HNcSCC increases with immunosuppression, nodal size >6 cm, ≥5 nodal metastases, and bilateral disease. A simple DMR risk score estimated prior to treatment may be clinically useful.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Head & Neck published by Wiley Periodicals LLC.
Références
Yang DD, Borsky K, Jani C, et al. Trends in keratinocyte skin cancer incidence, mortality and burden of disease in 33 countries between 1990 and 2017. Br J Dermatol. 2023;188(2):237‐246.
Alam M, Ratner D. Cutaneous squamous‐cell carcinoma. N Engl J Med. 2001;344(13):975‐983.
Ch'ng S, Maitra A, Allison RS, et al. Parotid and cervical nodal status predict prognosis for patients with head and neck metastatic cutaneous squamous cell carcinoma. J Surg Oncol. 2008;98(2):101‐105.
Hirshoren N, Danne J, Dixon BJ, et al. Prognostic markers in metastatic cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2017;39(4):772‐778.
Schmidt C, Martin JM, Khoo E, Plank A, Grigg R. Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center. Head Neck. 2015;37(12):1808‐1815.
Veness MJ, Palme CE, Morgan GJ. High‐risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease. Cancer. 2006;106(11):2389‐2396.
Ebrahimi A, Clark JR, Lorincz BB, Milross CG, Veness MJ. Metastatic head and neck cutaneous squamous cell carcinoma: defining a low‐risk patient. Head Neck. 2012;34(3):365‐370.
Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope. 2005;115:870‐875, 875.
Wang JT, Palme CE, Morgan GJ, Gebski V, Wang AY, Veness MJ. Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: improved survival with the addition of adjuvant radiotherapy. Head Neck. 2012;34(11):1524‐1528.
Porceddu SV, Bressel M, Poulsen MG, et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high‐risk cutaneous squamous cell carcinoma of the head and neck: The Randomized Phase III TROG 05.01 trial. J Clin Oncol. 2018;36(13):1275‐1283.
Sun XS, Michel C, Babin E, et al. Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC. Future Oncol. 2018;14(9):877‐889.
Florescu C, Thariat J. Local ablative treatments of oligometastases from head and neck carcinomas. Crit Rev Oncol Hematol. 2014;91(1):47‐63.
Young ER, Diakos E, Khalid‐Raja M, Mehanna H. Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: systematic review and meta‐analysis. Clin Otolaryngol. 2015;40(3):208‐218.
Migden MR, Rischin D, Schmults CD, et al. PD‐1 blockade with cemiplimab in advanced cutaneous squamous‐cell carcinoma. N Engl J Med. 2018;379(4):341‐351.
Senft A, Hoekstra OS, Witte BI, Leemans CR, de Bree R. Screening for distant metastases in head and neck cancer patients using FDG‐PET and chest CT: validation of an algorithm. Eur Arch Otorhinolaryngol. 2016;273(9):2643‐2650.
de Bree R, Senft A, Coca‐Pelaz A, et al. Detection of distant metastases in head and neck cancer: changing landscape. Adv Ther. 2018;35(2):161‐172.
McLean LS, Lim AM, Bressel M, et al. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. Med J Aust. 2024;220(2):80‐90.
Hosokawa S, Funai K, Sugiyama K, et al. Survival outcomes after surgical resection of pulmonary metastases of head and neck tumours. J Laryngol Otol. 2016;130(3):291‐295.
Oki T, Hishida T, Yoshida J, et al. Survival and prognostic factors after pulmonary metastasectomy of head and neck cancer: what are the clinically informative prognostic indicators? Eur J Cardiothorac Surg. 2019;55(5):942‐947.
Miyazaki T, Hasegawa Y, Hanai N, et al. Survival impact of pulmonary metastasectomy for patients with head and neck cancer. Head Neck. 2013;35(12):1745‐1751.
Winter H, Meimarakis G, Hoffmann G, et al. Does surgical resection of pulmonary metastases of head and neck cancer improve survival? Ann Surg Oncol. 2008;15(10):2915‐2926.
Pasalic D, Betancourt‐Cuellar SL, Taku N, et al. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck. 2020;42(8):1939‐1953.